Cardiol Therapeutics Inc. ( (CRDL) ) has released its Q1 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead product CardiolRx™ in clinical development. The latest earnings report for the three months ended March 31, 2025, shows a net loss of $8.29 million, a slight improvement from the $9.18 million loss in the same period last year. The company reported a decrease in cash and cash equivalents to $23.29 million from $30.58 million at the end of 2024. Key financial metrics include operating expenses of $8.43 million and interest income of $248,269. Despite the losses, Cardiol continues to advance its clinical programs, including the Phase III MAVERIC trial for recurrent pericarditis and the development of CRD-38 for heart failure. Looking ahead, Cardiol’s management remains focused on advancing its clinical trials and exploring potential partnerships to support commercialization efforts.